Literature DB >> 24431460

Cognitive enhancing treatment with a PPARγ agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice.

Miroslav N Nenov1, Fernanda Laezza, Sigmund J Haidacher, Yingxin Zhao, Rovshan G Sadygov, Jonathan M Starkey, Heidi Spratt, Bruce A Luxon, Kelly T Dineley, Larry Denner.   

Abstract

Hippocampal network hyperexcitability is considered an early indicator of Alzheimer's disease (AD) memory impairment. Some AD mouse models exhibit similar network phenotypes. In this study we focused on dentate gyrus (DG) granule cell spontaneous and evoked properties in 9-month-old Tg2576 mice that model AD amyloidosis and cognitive deficits. Using whole-cell patch-clamp recordings, we found that Tg2576 DG granule cells exhibited spontaneous EPSCs that were higher in frequency but not amplitude compared with wild-type mice, suggesting hyperactivity of DG granule cells via a presynaptic mechanism. Further support of a presynaptic mechanism was revealed by increased I-O relationships and probability of release in Tg2576 DG granule cells. Since we and others have shown that activation of the peroxisome proliferator-activated receptor gamma (PPARγ) axis improves hippocampal cognition in mouse models for AD as well as benefitting memory performance in some humans with early AD, we investigated how PPARγ agonism affected synaptic activity in Tg2576 DG. We found that PPARγ agonism normalized the I-O relationship of evoked EPSCs, frequency of spontaneous EPSCs, and probability of release that, in turn, correlated with selective expression of DG proteins essential for presynaptic SNARE function that are altered in patients with AD. These findings provide evidence that DG principal cells may contribute to early AD hippocampal network hyperexcitability via a presynaptic mechanism, and that hippocampal cognitive enhancement via PPARγ activation occurs through regulation of presynaptic vesicular proteins critical for proper glutamatergic neurotransmitter release, synaptic transmission, and short-term plasticity.

Entities:  

Keywords:  Alzheimer's; SNARE proteins; animal model; mass spectrometry; patch clamp; synaptic plasticity

Mesh:

Substances:

Year:  2014        PMID: 24431460      PMCID: PMC3891946          DOI: 10.1523/JNEUROSCI.3413-13.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  68 in total

1.  Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4.

Authors:  Rudi K Tannenberg; Heather L Scott; Anthony E G Tannenberg; Peter R Dodd
Journal:  Neurochem Int       Date:  2006-06-30       Impact factor: 3.921

2.  Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins.

Authors:  Kelly T Dineley; Xuefeng Xia; Duy Bui; J David Sweatt; Hui Zheng
Journal:  J Biol Chem       Date:  2002-03-23       Impact factor: 5.157

3.  Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins.

Authors:  S L Eastwood; P J Harrison
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

4.  Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.

Authors:  Jennifer Rodriguez-Rivera; Larry Denner; Kelly T Dineley
Journal:  Behav Brain Res       Date:  2010-08-13       Impact factor: 3.332

5.  C-terminal complexin sequence is selectively required for clamping and priming but not for Ca2+ triggering of synaptic exocytosis.

Authors:  Yea Jin Kaeser-Woo; Xiaofei Yang; Thomas C Südhof
Journal:  J Neurosci       Date:  2012-02-22       Impact factor: 6.167

6.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.

Authors:  Xinmin Zhang; Duncan T Odom; Seung-Hoi Koo; Michael D Conkright; Gianluca Canettieri; Jennifer Best; Huaming Chen; Richard Jenner; Elizabeth Herbolsheimer; Elizabeth Jacobsen; Shilpa Kadam; Joseph R Ecker; Beverly Emerson; John B Hogenesch; Terry Unterman; Richard A Young; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

7.  Deleterious effects of soluble amyloid-β oligomers on multiple steps of synaptic vesicle trafficking.

Authors:  Joohyun Park; Mirye Jang; Sunghoe Chang
Journal:  Neurobiol Dis       Date:  2013-03-21       Impact factor: 5.996

8.  Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; J Colleen Karlo; Gary E Landreth
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

9.  Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease.

Authors:  M Hoefer; S C Allison; G F Schauer; J M Neuhaus; J Hall; J N Dang; M W Weiner; B L Miller; H J Rosen
Journal:  Brain       Date:  2008-05-20       Impact factor: 13.501

10.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

View more
  25 in total

Review 1.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

2.  PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Wei-Chun J Hsu; Norelle C Wildburger; Sigmund J Haidacher; Miroslav N Nenov; Oluwarotimi Folorunso; Aditya K Singh; Brent C Chesson; Whitney F Franklin; Ibdanelo Cortez; Rovshan G Sadygov; Kelly T Dineley; Jay S Rudra; Giulio Taglialatela; Cheryl F Lichti; Larry Denner; Fernanda Laezza
Journal:  Exp Neurol       Date:  2017-05-15       Impact factor: 5.330

3.  Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice.

Authors:  Ge Jin; Lin Zhu; Peng Liu; Qian Xu; Yue Qi; Xiaoyu Zhou; Jikai Xu; Xuefei Ji; Tianyan Chi; Libo Zou
Journal:  J Physiol Sci       Date:  2019-02-14       Impact factor: 2.781

Review 4.  Insulin resistance in Alzheimer's disease.

Authors:  Kelly T Dineley; Jordan B Jahrling; Larry Denner
Journal:  Neurobiol Dis       Date:  2014-09-16       Impact factor: 5.996

Review 5.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 6.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

7.  Epigallocatechin Gallate Attenuates β-Amyloid Generation and Oxidative Stress Involvement of PPARγ in N2a/APP695 Cells.

Authors:  Zhao-Xu Zhang; Yan-Bing Li; Rui-Ping Zhao
Journal:  Neurochem Res       Date:  2016-11-26       Impact factor: 3.996

8.  Protection against alcohol-induced neuronal and cognitive damage by the PPARγ receptor agonist pioglitazone.

Authors:  Andrea Cippitelli; Esi Domi; Massimo Ubaldi; James C Douglas; Hong Wu Li; Gregory Demopulos; George Gaitanaris; Marisa Roberto; Paul D Drew; Cynthia J M Kane; Roberto Ciccocioppo
Journal:  Brain Behav Immun       Date:  2017-02-03       Impact factor: 7.217

Review 9.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

Review 10.  Nuclear receptors in neurodegenerative diseases.

Authors:  Rebecca Skerrett; Tarja Malm; Gary Landreth
Journal:  Neurobiol Dis       Date:  2014-05-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.